De Francesco Vincenzo, Ierardi Enzo, Hassan Cesare, Zullo Angelo
Vincenzo De Francesco, Enzo Ierardi, Gastroenterology Unit, Department of Medical Sciences, University of Foggia, Ospedali Riuniti, 71100 Foggia, Italy.
World J Gastrointest Pharmacol Ther. 2012 Aug 6;3(4):68-73. doi: 10.4292/wjgpt.v3.i4.68.
Helicobacter pylori (H. pylori) plays a crucial role in the pathogenesis of chronic active gastritis, peptic ulcer and gastric mucosa-associated lymphoid tissue-lymphoma, and is also involved in carcinogenesis of the stomach. H. pylori treatment still remains a challenge for physicians, since no current first-line therapy is able to cure the infection in all treated patients. Several factors may help in the eradication of therapy failure. We reviewed both bacterial and host factors involved in therapeutic management of the H. pylori infection. In addition, we evaluated data on the most successful therapy regimens - sequential and concomitant therapies - currently available for H. pylori eradication.
幽门螺杆菌（H. pylori）在慢性活动性胃炎、消化性溃疡和胃黏膜相关淋巴组织淋巴瘤的发病机制中起关键作用，还参与胃癌的发生。幽门螺杆菌治疗对医生来说仍然是一项挑战，因为目前没有一线治疗方法能够治愈所有接受治疗患者的感染。有几个因素可能有助于解决治疗失败的问题。我们综述了幽门螺杆菌感染治疗管理中涉及的细菌和宿主因素。此外，我们评估了目前可用于根除幽门螺杆菌的最成功治疗方案——序贯疗法和联合疗法——的数据。
